1054 related articles for article (PubMed ID: 17194517)
1. Sensitivity of butyrylcholinesterase knockout mice to (--)-huperzine A and donepezil suggests humans with butyrylcholinesterase deficiency may not tolerate these Alzheimer's disease drugs and indicates butyrylcholinesterase function in neurotransmission.
Duysen EG; Li B; Darvesh S; Lockridge O
Toxicology; 2007 Apr; 233(1-3):60-9. PubMed ID: 17194517
[TBL] [Abstract][Full Text] [Related]
2. Effects of acetylcholinesterase and butyrylcholinesterase inhibition on breathing in mice adapted or not to reduced acetylcholinesterase.
Boudinot E; Taysse L; Daulon S; Chatonnet A; Champagnat J; Foutz AS
Pharmacol Biochem Behav; 2005 Jan; 80(1):53-61. PubMed ID: 15652380
[TBL] [Abstract][Full Text] [Related]
3. Butyrylcholinesterase and the control of synaptic responses in acetylcholinesterase knockout mice.
Girard E; Bernard V; Minic J; Chatonnet A; Krejci E; Molgó J
Life Sci; 2007 May; 80(24-25):2380-5. PubMed ID: 17467011
[TBL] [Abstract][Full Text] [Related]
4. Oral administration of pyridostigmine bromide and huperzine A protects human whole blood cholinesterases from ex vivo exposure to soman.
Gordon RK; Haigh JR; Garcia GE; Feaster SR; Riel MA; Lenz DE; Aisen PS; Doctor BP
Chem Biol Interact; 2005 Dec; 157-158():239-46. PubMed ID: 16256090
[TBL] [Abstract][Full Text] [Related]
5. Comparative effects of huperzine A, donepezil and rivastigmine on cortical acetylcholine level and acetylcholinesterase activity in rats.
Liang YQ; Tang XC
Neurosci Lett; 2004 May; 361(1-3):56-9. PubMed ID: 15135892
[TBL] [Abstract][Full Text] [Related]
6. Effect of butyrylcholinesterase genotype on the response to rivastigmine or donepezil in younger patients with Alzheimer's disease.
Blesa R; Bullock R; He Y; Bergman H; Gambina G; Meyer J; Rapatz G; Nagel J; Lane R
Pharmacogenet Genomics; 2006 Nov; 16(11):771-4. PubMed ID: 17047484
[TBL] [Abstract][Full Text] [Related]
7. Butyrylcholinesterase, paraoxonase, and albumin esterase, but not carboxylesterase, are present in human plasma.
Li B; Sedlacek M; Manoharan I; Boopathy R; Duysen EG; Masson P; Lockridge O
Biochem Pharmacol; 2005 Nov; 70(11):1673-84. PubMed ID: 16213467
[TBL] [Abstract][Full Text] [Related]
8. Resistance to organophosphorus agent toxicity in transgenic mice expressing the G117H mutant of human butyrylcholinesterase.
Wang Y; Boeck AT; Duysen EG; Van Keuren M; Saunders TL; Lockridge O
Toxicol Appl Pharmacol; 2004 May; 196(3):356-66. PubMed ID: 15094306
[TBL] [Abstract][Full Text] [Related]
9. Excessive hippocampal acetylcholine levels in acetylcholinesterase-deficient mice are moderated by butyrylcholinesterase activity.
Hartmann J; Kiewert C; Duysen EG; Lockridge O; Greig NH; Klein J
J Neurochem; 2007 Mar; 100(5):1421-9. PubMed ID: 17212694
[TBL] [Abstract][Full Text] [Related]
10. Cholinesterase inhibitors proposed for treating dementia in Alzheimer's disease: selectivity toward human brain acetylcholinesterase compared with butyrylcholinesterase.
Pacheco G; Palacios-Esquivel R; Moss DE
J Pharmacol Exp Ther; 1995 Aug; 274(2):767-70. PubMed ID: 7636741
[TBL] [Abstract][Full Text] [Related]
11. The butyrylcholinesterase knockout mouse as a model for human butyrylcholinesterase deficiency.
Li B; Duysen EG; Carlson M; Lockridge O
J Pharmacol Exp Ther; 2008 Mar; 324(3):1146-54. PubMed ID: 18056867
[TBL] [Abstract][Full Text] [Related]
12. Reduced acetylcholine receptor density, morphological remodeling, and butyrylcholinesterase activity can sustain muscle function in acetylcholinesterase knockout mice.
Adler M; Manley HA; Purcell AL; Deshpande SS; Hamilton TA; Kan RK; Oyler G; Lockridge O; Duysen EG; Sheridan RE
Muscle Nerve; 2004 Sep; 30(3):317-27. PubMed ID: 15318343
[TBL] [Abstract][Full Text] [Related]
13. Protection of red blood cell acetylcholinesterase by oral huperzine A against ex vivo soman exposure: next generation prophylaxis and sequestering of acetylcholinesterase over butyrylcholinesterase.
Haigh JR; Johnston SR; Peppernay A; Mattern PJ; Garcia GE; Doctor BP; Gordon RK; Aisen PS
Chem Biol Interact; 2008 Sep; 175(1-3):380-6. PubMed ID: 18572153
[TBL] [Abstract][Full Text] [Related]
14. Molecular modeling, docking and ADMET studies applied to the design of a novel hybrid for treatment of Alzheimer's disease.
da Silva CH; Campo VL; Carvalho I; Taft CA
J Mol Graph Model; 2006 Oct; 25(2):169-75. PubMed ID: 16413803
[TBL] [Abstract][Full Text] [Related]
15. Cholinesterase inhibitors modify the activity of intrinsic cardiac neurons.
Darvesh S; Arora RC; Martin E; Magee D; Hopkins DA; Armour JA
Exp Neurol; 2004 Aug; 188(2):461-70. PubMed ID: 15246845
[TBL] [Abstract][Full Text] [Related]
16. Comparative studies of huperzine A, donepezil, and rivastigmine on brain acetylcholine, dopamine, norepinephrine, and 5-hydroxytryptamine levels in freely-moving rats.
Liang YQ; Tang XC
Acta Pharmacol Sin; 2006 Sep; 27(9):1127-36. PubMed ID: 16923332
[TBL] [Abstract][Full Text] [Related]
17. Prolonged toxic effects after cocaine challenge in butyrylcholinesterase/plasma carboxylesterase double knockout mice: a model for butyrylcholinesterase-deficient humans.
Duysen EG; Lockridge O
Drug Metab Dispos; 2011 Aug; 39(8):1321-3. PubMed ID: 21540357
[TBL] [Abstract][Full Text] [Related]
18. Physiological and neurobehavioral effects of cholinesterase inhibition in healthy adults.
Morasch KC; Aaron CL; Moon JE; Gordon RK
Physiol Behav; 2015 Jan; 138():165-72. PubMed ID: 25455867
[TBL] [Abstract][Full Text] [Related]
19. Donepezil for Alzheimer's disease.
Benjamin B; Burns A
Expert Rev Neurother; 2007 Oct; 7(10):1243-9. PubMed ID: 17939763
[TBL] [Abstract][Full Text] [Related]
20. Cerebrospinal fluid levels of biomarkers and activity of acetylcholinesterase (AChE) and butyrylcholinesterase in AD patients before and after treatment with different AChE inhibitors.
Parnetti L; Amici S; Lanari A; Romani C; Antognelli C; Andreasen N; Minthon L; Davidsson P; Pottel H; Blennow K; Gallai V
Neurol Sci; 2002 Sep; 23 Suppl 2():S95-6. PubMed ID: 12548360
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
